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Molecular mimicry between self and microbial components has been proposed as the pathogenic mechanism of autoimmune
diseases, and this hypothesis is proven in Guillain-Barr´ e syndrome. Guillain-Barr´ e syndrome, the most frequent cause of acute
neuromuscular paralysis, sometimes occurs after Campylobacter jejuni enteritis. Gangliosides are predominantly cell-surface
glycolipids highlyexpressed in nervous tissue,whilstlipo-oligosaccharides are majorcomponentsofthe Gram-negative bacterium
C. jejuni outer membrane. IgG autoantibodies to GM1 ganglioside were found in the sera from patients with Guillain-Barr´ e
syndrome. Molecular mimicry was demonstrated between GM1 and lipo-oligosaccharide of C. jejuni isolated from the patients.
Disease models by sensitizationof rabbits with GM1 and C. jejuni lipo-oligosaccharide were established. Guillain-Barr´ es y n d r o m e
provided the ﬁrst veriﬁcation that an autoimmune disease is triggered by molecular mimicry. Its disease models are helpful to
further understand the molecular pathogenesis as well as to develop new treatments in Guillain-Barr´ es y n d r o m e .
1.Introduction
In the 19th century, Robert Koch postulated a causal
relationship between a pathogenic microbe and a disease [1].
This was later extended to the role of autoantibodies in the
pathogenesis of human disease by Witebsky et al. [2]. In
1957,theyproposedthefulﬁllmentofseveralcriteriatoproof
the pathogenic eﬀects of autoantibodies, namely, the direct
demonstration of free, circulating, or cell-bound antibodies
by indirect means, the recognition of speciﬁc antigen against
which the antibody is directed, the production of antibodies
against the same antigen in experimental animals and ﬁnally
the appearance of pathological changes in the corresponding
tissues of an actively sensitized experimental model that is
similar to that in the human disease.
Taking into account both Koch’s and Witebsky’s pos-
tulates, the term “molecular mimicry” was proposed as a
mechanism by which infectious agents trigger an immune
response against autoantigens, resulting in the development
of autoimmune diseases. Similar criteria must be satisﬁed to
conclude that a disease is triggered by molecular mimicry
[3]. They are as follows: (i) the establishment of an epidemi-
ological association between the infectious agent and the
immune-mediated disease; (ii) the identiﬁcation of T cells
or antibodies directed against the patient’s target antigens;
(iii) the identiﬁcation of microbial mimics of the target
antigen; (iv) reproduction of the disease in an animal model.
Although there have been a number of diseases proposed to
exhibit the mechanism of molecular mimicry, none has been
proven in examples of human diseases based on fulﬁlment of
all four criteria [4].
Guillain-Barr´ e syndrome (GBS), characterized by limb
weakness and areﬂexia, has become the most frequent cause
of acute ﬂaccid paralysis since the near elimination of
poliomyelitis in the world [5]. Most GBS patients have
had either gastrointestinal or upper respiratory symptoms
one to three weeks prior to the onset of their neurological
symptoms, making GBS the prototype of postinfectious2 Journal of Biomedicine and Biotechnology
autoimmune diseases. GBS can be classiﬁed into two major
subtypes, acute inﬂammatory demyelinating polyneuropa-
thy (AIDP) and acute motor axonal neuropathy (AMAN)
depending on whether the myelin or the axonal compo-
nents of the peripheral nerves are aﬀected. Experimental
autoimmune neuritis (EAN) resembles AIDP clinically and
pathologically. EAN can be transferred to animals by T cells
sensitized to peripheral nerve proteins such as P2 protein.
However, no investigators have shown conclusive evidence
that such autoreactive T-cell response is seen in patients with
GBS, indicating that EAN is not a true model of AIDP [6].
In this paper, we describe the development of a true model
of AMAN, which fulﬁlls all the four criteria of molecular
mimicry as well as Witebsky’s postulate as stated above. This
veriﬁes GBS as the ﬁrst paradigm of an autoimmune disease
triggered by molecular mimicry. We also discuss how this
disease model has helped uncover the precise mechanism of
muscle weakness in GBS, which will potentially lead to the
development of better treatments.
2.P r oofofM olecularM imicryTheory
Gram-negative bacterium Campylobacter jejuni, al e a d i n g
cause of acute gastroenteritis, is the most common
antecedent microorganism in GBS. A prospective case-
control study detected evidence of recent C. jejuni infection
in26%ofpatientswithGBSincomparisonto only2% ofthe
household controls (a member of the patient’s household)
and 1% of the age-matched hospital controls [7]. That study
established an epidemiological association between C. jejuni
infection and GBS. A study showed that C. jejuni infection
was associated with AMAN, but not AIDP [8], although this
ﬁnding has yet to be veriﬁed by other investigators.
Autoantibodies are considered to be the pathogenic
components which trigger GBS because plasma exchange is
proven to be an eﬀective treatment in GBS [9]. Ganglio-
sides constitute a large family of predominantly cell-surface
glycosphingolipids bearing a ceramide moiety anchored in
the external leaﬂet of the lipid bilayer and a sialylated
oligosaccharide core exposed in the extracellular space.
Autopsy studies show that, in AMAN, IgG is deposited on
the axolemma of the spinal anterior root [10], indicating
that IgG, which binds eﬀectively with complement, is an
important factor in the development of AMAN. Patients
who develop AMAN subsequent to C. jejuni enteritis have
IgG antibodies against GM1 [11]. Their autoantibody titres
decrease as the clinical time course progresses. In contrast,
patients who have C. jejuni enteritis with no neurological
sequelae did not have similar autoantibodies. These ﬁndings
suggest that GM1 is an autoantigen for IgG antibodies
in patients with AMAN subsequent to C. jejuni enteritis.
IgG anti-GD1a antibodies are also associated with AMAN
subsequent to C. jejuni infection [12].
Lipo-oligosaccharides (LOSs) are a family of phosphory-
lated glycolipids anchored on the outersurface membrane of
C. jejuni.AC. jejuni strain isolated from an AMAN patient
carrying IgG anti-GM1 antibody expressed an oligosaccha-
ride structure [Gal β1–3 GalNAc β1–4 (NeuAcα2-3) Galβ]
GM1
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Figure 1:Carbohydrate mimicrybetween gangliosidesandCampy-
lobacter jejuni lipo-oligosaccharides (LOSs). The terminal tetrasac-
charideofGM1-likeLOSisidenticaltothatofGM1(shownbydash
lines).
which protruded from the LOS core (Figure 1)[ 13]. This
terminal structure was identical to that of the terminal
tetrasaccharide of the GM1 ganglioside. This was the ﬁrst
deﬁnitive evidence of molecular mimicry between human
peripheral nerves and antecedent agents in GBS. This
strain also carried a GD1a-like LOS [14]. Further evidence
regarding the role of antiganglioside antibodies in GBS came
in the form of adverse reactions to therapeutic gangliosides
extracted from bovine brain tissue. These were previously
used in the treatment of various neurological disorders. In a
study investigating sevenpatientswho developedAMANfol-
lowing intravenous bovine brain ganglioside administration,
anti-GM1 antibodies were discovered in six patients and
anti-GD1a and -GT1b antibodies in one patient [15]. These
ﬁndings set the scene for the work done in the development
of a suitable experimental animal model for GBS.
An AMAN model was established by the sensitization
of rabbits with a bovine brain ganglioside mixture that
included GM1 or with an isolated GM1 [16]. The rabbits
developed high titres of IgG anti-GM1 antibodies, fol-
lowed by an acute onset of ﬂaccid limb weakness with a
monophasic course. Pathological ﬁndings in their peripheral
nerves showed predominant Wallerian-like degeneration
with neither lymphocytic inﬁltration nor demyelination
features. IgG was deposited on the axons of the anterior
roots, internodal axolemmas, and nodes of Ranvier. Cauda
equina and spinal nerve root specimens from the paralyzed
rabbits showed macrophage inﬁltration in the periaxonal
space [17]. Surrounding myelin sheaths were almost intact.
These ﬁndings correspond well with pathological ﬁndings





Figure 2: Characteristic ﬁndings for the acute motor axonal neuropathy rabbit model. (a) Rabbit with ﬂaccid limb weakness induced
by sensitization with Campylobacter jejuni lipo-oligosaccharide. Its body is splayed, all extremities extended, head on the ﬂoor not sitting
upright in the usual compact, hunched posture. (b) Longitudinal section of the cauda equina. The nodes of Ranvier are stained selectively
with protein G (arrowheads). Scale bar, 10μm. (c) Electron micrograph of a nerve ﬁber with macrophage inﬁltration. A macrophage (M)
occupies the periaxonal space between the atrophic axon (A) and surrounding myelin sheath which appears almost normal.Scale bar, 5μm.
(d) Wallerian-likedegeneration of nerve ﬁbers in a paralyzed rabbit killed 39 days after onset. Sciatic nerve cross section with toluidine blue
stain. Myelin ovoids produced by Wallerian-like degeneration of myelinated ﬁbers are present (arrowheads). Scale bar, 10μm. Muscle Nerve
35:691–711, Copyright 2007, John Wiley & Sons,Inc.
Themoststraightforward wayofverifyingthatmolecular
mimicry between microbes and autoantigens cause GBS
is to establish a GBS model by the immunization of
animals with components of antecedent infectious agents.
An AMAN model was established by the immunization of
rabbits with C. jejuni LOS bearing a GM1-like structure
[19]. On sensitization with this GM1-like LOS, rabbits
developed IgG anti-GM1 antibodies and subsequent ﬂaccid
limb weakness (Figure 2). Their nerve roots had occasional
macrophages in the periaxonal spaces surrounded by an
almost intact myelin sheath. Axons of these nerve ﬁbres
showed various degrees of degeneration. Demyelination and
remyelination features were rare. These ﬁndings, which
are compatible with the features of human AMAN, pro-
vided the evidence that rabbits inoculated with C. jejuni
LOS constitute a valid AMAN model. This represents the
ﬁrst replica of human autoimmune disease in an ani-
mal model immunized by a microbial mimic of a self-
antigen.
In contrast to the active immunization models above,
a passive transfer model was developed to further proof
the molecular mimicry theory. Ex vivo nerve-muscle prepa-
rations from GD1a-overexpressing mice were exposed to
mouse IgG anti-GD1a monoclonal antibodies in the pres-
ence of a complement source [20]. This allowed the
morphological and neurophysiological features of such an
exposure to be investigated further. Dense antibody and
complement deposits were shown to only be present on the
presynaptic motor axons. This was accompanied by severe
ultrastructural damage and electrophysiological blockade
of motor nerve terminal function. A similar paralyzing
eﬀect was found when human sera with IgG anti-GD1a
reactivity were used instead. The nature of this injury is also
complement dependent. These ﬁndings indicate that anti-
GD1a antibodies arise from molecular mimicry and are the
likely trigger of peripheral nerve injury.
In summary, GBS is the ﬁrst true model of molecular
mimicry having fulﬁlled all four criteria as follows: (i)
establishment of an epidemiological association between
GBS and C. jejuni infection by a prospective case-control
study [7], (ii) identiﬁcation of autoantibodies against GM1
and GD1a gangliosides in patients with AMAN subsequent
to C. jejuni enteritis [11, 12], (iii) identiﬁcation of molecular
mimicry between GM1 or GD1a and LOS of C. jejuni
isolated from AMAN [13, 14], and (iv) reproduction of
the AMAN models by active immunization of rabbits4 Journal of Biomedicine and Biotechnology
with GM1 or the C. jejuni LOS [16, 19]a sw e l la sb y
passive transfer of anti-GD1a antibodies in mice [20].
This makes GBS the ﬁrst disease in humans to verify
that an autoimmune disease is triggered by molecular
mimicry.
3.Developmentof NewTreatments
In both human and rabbit AMAN, the earliest pathological
changes consist of lengthening of the node of Ranvier with
distortion of the paranodal myelin [17, 21]. Voltage-gated
sodium channel dysfunction is postulated to occur at the
nodes of Ranvier [22]. There has been some controversy
as to whether anti-GM1 antibodies truly aﬀect sodium
channels at the nodes of Ranvier [23, 24]. In the spinal
anterior roots of AMAN rabbits, IgG antibodies bind to
nodes of Ranvier, where GM1 is highly expressed. This
binding of autoantibodies triggers complement activation
with deposition of C3 components followed by membrane
attack complex formation at the nodal axolemma. The
sodium channel clusters are then altered by the destruction
of their stabilizing components which include the axonal
cytoskeleton at nodes, Schwann cell microvilli, and paran-
odal axo-glial junctions. This apparent “disappearance” of
sodium channel clusters signiﬁcantly lowers the safety factor
for impulse transmission, thus causing muscle weakness in
AMAN. This is a novel mechanism by which autoantibodies
can modulate sodium channel properties to cause the
development of certain neurological disorders.
Plasma exchange and intravenous immunoglobulins
are equally eﬀective treatments in GBS [9]. Despite the
administration of either immunotherapeutic agent, there are
still mortality and signiﬁcant morbidity in patients with
GBS; 3–10% death and 20% immobile after 6 months
[5]. Research into new treatment options to improve the
ﬁnal outcome of GBS is urgently required. As previously
described, complement activation products are deposited
on the outer membrane of Schwann cells in AIDP patients
[25], and on the axolemma of motor ﬁbres in AMAN [10].
These postmortem studies show that complement activation
followed by membrane attack complex formation is an
important mechanism for the glial and neuronal injury seen
in GBS. This suggests that complement inhibitors have the
potential of being a new, more rational treatment for GBS.
Nafamostat mesilate is a synthetic serine protease
inhibitor that has been used clinically in Japan for over
20 years with no serious adverse eﬀects to patients. As the
complement system contains several serine proteases such as
C1r, C1s, and C3/C5 convertases, nafamostat mesilate can
eﬃciently inhibit these serine proteases, thus blocking the
formation of the membrane attack complex. This inhibition
of complement deposition and sodium channel cluster
disappearance has been demonstrated in AMAN rabbits
[26]. These experimental ﬁndings along with the autopsy
ﬁndingswouldjustifyestablishing clinicaltrialstoinvestigate
the use ofcomplementinhibitors as a potential treatment for
GBS.
4.Conclusion
In this paper, we have demonstrated how the animal model
of AMAN has contributed to the proof of the molecular
mimicry theory. However, the same cannot be said of AIDP.
Onlytheﬁrstcriterionhasbeenachievedwiththeassociation
of AIDP with cytomegalovirus infection. Until the target
antigen in AIDP is ascertained, identiﬁcation of its microbial
mimics and reproduction of the disease in an animal model
remain unresolved.
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